Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Blood (2024) 144 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2024-205614

Published: 2024

Journal Articles

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 283.

https://doi.org/10.1182/blood-2024-210314

Published: 2024

Journal Articles

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Karen Sweiss, Jay R. Hydren, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Pritesh Patel, Douglas W. Sborov, Jennifer M. Ahlstrom, Lisa Sharp, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5144.

https://doi.org/10.1182/blood-2024-210437

Published: 2024

Journal Articles

Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A -Rearranged B-Cell Acute Lymphoblastic Leukemia

Blood (2024) 144 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2024-205461

Published: 2024

Journal Articles

Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

Karen Sweiss, Craig C Hofmeister, John G. Quigley, Jaleel G. Sweis, Kaily Kurzweil, Douglas W. Sborov, Lisa Sharp, Gregory S Calip, Lucas Maahs, Ana Maria Avila, Chukwuemeka Uzoka, Elizabeth Ilo, Elliot Wolf, Damiano Rondelli, Pritesh Patel

Blood (2022) 140 (Supplement 1): 5252–5253.

https://doi.org/10.1182/blood-2022-171045

Published: 2022

Journal Articles

G-CSF Improves Stable Engraftment in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Hematopoietic Stem Cell Transplantation

Lucas Maahs, Karen Sweiss, Pritesh Patel, Sally Campbell-Lee, Nadim Mahmud, Victor R. Gordeuk, Damiano Rondelli, Santosh L. Saraf

Blood (2022) 140 (Supplement 1): 4747–4748.

https://doi.org/10.1182/blood-2022-160050

Published: 2022

Journal Articles

A Phase Ib Study of the Safety and Efficacy of Venetoclax When Combined with Escalating Doses of Omacetaxine in Patients with Relapsed/Refractory Acute Myeloid Leukemia Failing Treatment with Venetoclax-Containing Regimens (VEN-OM)

Ana Maria Avila, Saad Arain, Karen Sweiss, Pritesh Patel, Samin Houshyar, Gregory S Calip, Irum Khan, Paul G. Rubinstein, Chukwuemeka Uzoka, John G. Quigley

Blood (2022) 140 (Supplement 1): 11774–11775.

https://doi.org/10.1182/blood-2022-165565

Published: 2022

Journal Articles

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Karen Sweiss, Santosh L. Saraf, Alison Doane, Monika Mandava, Ryan Sun, Mahir Khan, Zacharie Paul Charles Hamilton, Jaleel G. Sweis, Victor R. Gordeuk, Damiano Rondelli, Lisa Sharp, Pritesh Patel

Blood (2022) 140 (Supplement 1): 5123–5124.

https://doi.org/10.1182/blood-2022-171103

Published: 2022

Journal Articles

Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study

Saad Arain, Ana Maria Avila, Sonia Christian, Pritesh Patel, Karen Sweiss, Brian Parkin, Santosh L. Saraf, Paul G. Rubinstein, Gregory S Calip, John G. Quigley

Blood (2022) 140 (Supplement 1): 11725–11726.

https://doi.org/10.1182/blood-2022-165615

Published: 2022

Journal Articles

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Karen Sweiss, Craig C Hofmeister, Maria Zappia, Maxim Frolov, Elizaveta Benevolenskaya, John G. Quigley, Shrihari Kadkol, Douglas W. Sborov, Damiano Rondelli, Pritesh Patel

Blood (2022) 140 (Supplement 1): 7304–7305.

https://doi.org/10.1182/blood-2022-170936

Published: 2022

Journal Articles

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Ivan J. Huang, Rosa Yeh, Karen Sweiss, Pritesh Patel, Alexandre Vinaud Hirayama, Erik L. Kimble, Krishna R. Juluri, Mazyar Shadman, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 12725–12727.

https://doi.org/10.1182/blood-2022-156751

Published: 2022

Journal Articles

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Lucas Maahs, Pritesh Patel, Karen Sweiss, Chukwuemeka Uzoka, Nadim Mahmud, Ana Maria Avila, Matthew Koshy, Damiano Rondelli

Blood (2022) 140 (Supplement 1): 12913–12914.

https://doi.org/10.1182/blood-2022-163424

Published: 2022

Journal Articles

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Samin Houshyar, Betul Gok Yavuz, Pritesh Patel, Nadim Mahmud, Karen Sweiss, Irum Khan, Santosh L. Saraf, Damiano Rondelli, Anwar Khan, John G. Quigley

Blood (2022) 140 (Supplement 1): 5957–5958.

https://doi.org/10.1182/blood-2022-170100

Published: 2022

Journal Articles

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Karen Sweiss, Pritesh Patel, Janet Guo, Kyeongmin Kim, Kasey Hill, Nicole Abbott, Jeremy Johnson, Donald Irby, John G. Quigley, Damiano Rondelli, R Donald Harvey, Ajay K. Nooka, Madhav Dhodapkar, Jonathan L. Kaufman, Nisha S. Joseph, Sagar Lonial, Douglas W. Sborov, Mitch A Phelps, Craig C Hofmeister

Blood (2022) 140 (Supplement 1): 5988–5990.

https://doi.org/10.1182/blood-2022-170778

Published: 2022

Journal Articles

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Blood (2022) 140 (Supplement 1): 4323–4324.

https://doi.org/10.1182/blood-2022-159501

Published: 2022

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-143342

Published: 2020

Journal Articles

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Karen Sweiss, PharmD, Eric Wenzler, Hung H Nguyen, MLS, Avadhut D Joshi, PhD, Rosa Yeh, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Donald Irby, PhD, Mitch A. Phelps, PhD, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-143430

Published: 2020

Journal Articles

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Karen Sweiss, PharmD, Benjamin G Barwick, PhD, Gregory Sampang Calip, PharmD,MPH,PhD, Damiano Rondelli, MD, Craig C Hofmeister, MDMPH, Pritesh Patel, MB, ChB

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-143422

Published: 2020

Journal Articles

Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia

Saad Arain, MD, Eshana Shah, MD, Betul Gok Yavuz, MD PhD, Sarah Stettner, Gregory Sampang Calip, PharmD,MPH,PhD, Irum Khan, MD, Pritesh Patel, MB, ChB, John G. Quigley

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136708

Published: 2020

Journal Articles

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, Jeremy Johnson, PharmD, PhD, Jaime Holden, BFA, Paulina Lewkowski, BS, Iryna Mialik, AS, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 1980.

https://doi.org/10.1182/blood-2019-131886

Published: 2019

NARROW

Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma

First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A -Rearranged B-Cell Acute Lymphoblastic Leukemia

Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

G-CSF Improves Stable Engraftment in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Hematopoietic Stem Cell Transplantation

A Phase Ib Study of the Safety and Efficacy of Venetoclax When Combined with Escalating Doses of Omacetaxine in Patients with Relapsed/Refractory Acute Myeloid Leukemia Failing Treatment with Venetoclax-Containing Regimens (VEN-OM)

Pre-Transplant Assessment of Adult Sickle Cell Patients Shows a High Prevalence of Psychosocial Frailties before Allogeneic Stem Cell Transplant

Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study

Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Long-Term Adverse Events of Total Marrow Irradiation (TMI)-Based Conditioning Chemotherapy in Hematopoietic Stem Cell Transplant Recipients Treated on a Phase I/II Trial

Safety and Efficacy of the Addition of the Protein Translation Inhibitor Omacetaxine to Induction with Cytarabine and Idarubicin in Newly Diagnosed AML

Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study)

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

High Rates of Varicella Zoster Virus Antibody Seroconversion and Persistence after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Comparison of Individualized Versus MAP-Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant

Increased DNA Repair Gene Expression Correlates with MYC Expression and Inferior Progression-Free Survival in Multiple Myeloma Patients

Hematologic Predictors of Outcomes in Patients Undergoing Intensive Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia

Low Pre-Treatment Hemoglobin and Creatinine Clearance Correlate with Worse Overall Survival, Treatment-Related Mortality, and Regimen-Related Toxicities in Patients Undergoing a Reduced-Intensity Allogeneic Stem Cell Transplantation with Fludarabine and Melphalan

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only